Descripción

A webinar with the exceptional participation of Dr. Jean-Philippe Wagner Since September 2017, 17 patients from our institution accepted to pay for OncoDNA testing. In France OncoDNA’s analyses are not reimbursed yet and when we propose this innovative approach to patients they usually accept (even if their incomes are restricted). The presentation of Dr. Wagner will focus on the social and medical profiles of the patients, the moment the tests were done and how I decided to use the results of those analyses. he showed that such a testing should be done as early as possible (even in the adjuvant setting in young high-risk breast cancer patients) because of multi-resistance to drugs that was highlighted for all the patients tested, which explained relatively short relapse after the end of the adjuvant chemotherapy. In his opinion, OncoDNA’s analyses should be done just after the first relapse. The more so as new treatments like palbociclib for breast cancer are now available in France both for first and second line of treatment at a cost of 2800 Euros a month. Knowing also that this kind of therapies are given on an average of 24 months in the first line and 11 months in second line, the cost-effectiveness of this solution seems obvious to better identify the potential good and poor responders to these very expansive treatments for the National Health Insurance.